Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Brian Godman, Rickard E Malmström, Eduardo Diogene, Andy Gray, Sisira Jayathissa, Angela Timoney, Francisco Acurcio, Ali Alkan, Anna Brzezinska, Anna Bucsics, Stephen M Campbell, Jadwiga Czeczot, Winnie de Bruyn, Irene Eriksson, Faridah Aryani Md Yusof, Alexander E Finlayson, Jurij Fürst, Kristina Garuoliene, Augusto Guerra Júnior, Jolanta GulbinovičSaira Jan, Roberta Joppi, Marija Kalaba, Einar Magnisson, Laura McCullagh, Kaisa Miikkulainen, Gabriela Ofierska-Sujkowska, Hanne Bak Pedersen, Gisbert Selke, Catherine Sermet, Susan Spillane, Azuwana Supian, Ilse Truter, Vera Vlahović-Palčevski, Low Ee Vien, Elif H Vural, Janet Wale, Magdałene Władysiuk, Wenjie Zeng, Lars L Gustafsson

Research output: Contribution to journalArticle

73 Citations (Scopus)
69 Downloads (Pure)

Abstract

Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.
Original languageEnglish
Pages (from-to)77-94
Number of pages18
JournalExpert Review of Clinical Pharmacology
Volume8
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

    Fingerprint

Keywords

  • clinical pharmacology
  • critical drug evaluation
  • dabigatran
  • differential pricing
  • ivacaftor
  • managed entry agreements
  • new models
  • rational use of medicines
  • sofosbuvir
  • trastuzumab emtansine
  • adalimumab
  • etanercept
  • cancer therapy
  • cerebrovascular accident
  • cost effectiveness analysis
  • diabetes mellitus
  • drug industry
  • drug screening
  • drug utilization
  • embolism
  • France
  • health care system
  • health care utilization
  • heart atrium fibrillation
  • human
  • medical decision making
  • medicine
  • oncology
  • phase 3 clinical trial (topic)
  • reimbursement

Cite this